Lupin share news, announcements and annual reports
NSE: LUPINBSE: 500257Pharmaceuticals & BiotechnologyMid Cap
Lupin Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1993 on BSE, Sep 2001 on NSE
Last close ₹2,011.00up ₹21.10 (1.06%)BSE ₹2,009.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,989.90.
30 Oct: open ₹1,995.70, high ₹2,021.80, low ₹1,974.00
52-week range of traded prices to 30 Oct 2026
₹1,892.90Low, 23 Oct 2026₹2,529.50High, 16 Jul 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹91,961 Cr105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 16.63
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 15.11
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.10
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 30.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 28.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,59,66358.6% delivered
Lupin orders, deals and press releases
1,075 filed, newest first. Page 22 of 22.
Oct 2007
10 Oct · Business
Press release dated October 10, 2007, titled "Lupin acquires in Japan". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2007
27 Sep · Business
Press release dated September 27, 2007, titled "Lupin acquires pharmaceutical business of Rubamin". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Sep · Business
Press release dated September 12, 2007, titled "Lupin wins Ramipril product patent challenge at Federal Circuit". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2007
13 Aug · Business
Press release dated August 13, 2007, titled "Lupin appoints Ramesh Swaminathan as President Finance and Planning". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
31 Jul · Business
Press release dated July 31, 2007, titled "Lupin receives "Best New Manufacturer of the Year" Award from Amerisource Bergen". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jul · Business
Press release dated July 18, 2007, titled "Lupin receives DCGI Approval to conduct Combined Phase IIb/III Clinical Trials for it's herbal Psoriasis NCE". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jul · Business
Press release dated July 19, 2007, titled "Lupin FY 2007-08 Q1 Net Profit up 55% to Rs.784 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jul · Business
Press release dated July 17, 2007, titled "Lupin Receives US FDA Approval for Amlodipine". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jul · Business
Press release dated July 02, 2007, titled "Lupin gets MHRA Approval for Lisinopril in UK". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2007
14 Jun · Business
Press release dated June 14, 2007, titled "Lupin receives Final FDA Approval for Trandolapril". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
31 May · Business
Two press releases dated May 31, 2007, titled "Lupin and Symbiotee decide not to pursue their MoU" and "Lupin receives US FDA approval for Cefadroxil Capsules." The details of the press releases shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 May · Business
Press release dated May 21, 2007, titled "Lupin receives tentative US FDA Approval for Ziprasidone". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 May · Business
Press release dated May 15, 2007, titled "Lupin receives US FDA approval for Simvastatin Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 May · Business
Press release dated May 09, 2007, titled "Lupin and Symbiotec join hands on Steroids". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 May · Business
Press release dated May 09, 2007, titled "Lupin FY 2006-07 Net Profit up 65% to Rs.3021 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 May · Business
Press release dated May 08, 2007, titled "Lupin receives FDA Approval of Cefdinir for Oral Suspension, 250 mg/5mL, launches complete range in the US". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
27 Apr · Business
Collaboration between the Department of Science and Technology, Government of India and Lupin Limited for clinical development of the Company's Migraine and Psoriasis projects. Further the Company has submitted to the Exchange a copy of the press release dated April 27, 2007, titled "DST and Lupin join hands over Migraine Psoriasis". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Apr · Business
Press release dated April 12, 2007, titled "Lupin receives US FDA Approval for Novel Formulation of Suprax (R) Suspension". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Apr · Business
Press release, dated April 5, 2007, titled "Lupin finalizes patent sale agreement with Servier". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2007
13 Mar · Business
Press release dated March 13, 2007, titled "Lupin gets Marketing Approval for Cefpodoxime Proxetil in France". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2007
20 Feb · Business
An Agreement entered into by the Company for the sale of certain patent applications and related intellectual Property for Perindopril to Laboratories Servier of France. A copy of press release in this regard titled "Lupin sells Intellectual Property on Perindopril to Servier" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Feb · Business
Press release dated February 07, 2007, titled "Lupin receives US FDA approval for Sertraline". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2007
19 Jan · Business
Press release dated January 19,2007, titled "Lupin and Aspen decide not to pursue their MOU". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jan · Business
Press release, dated January 17, 2007, titled "Lupin FY 2006-07 Q3 Net Profit up by 27% at Rs. 560 mn." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jan · Business
Press release dated January 02,2007, titled "Lupin gets tentative US FDA approval for Sertraline". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.